CD200 deficiency or treatment with a CD200R1-blocking antibody resulted in an enhanced pathology in an experimental model of multiple sclerosis, while the administration of a CD200R1 agonist resulted in an attenuated pathology [26, 55]. The gene discussed is CD200R1; the disease is multiple sclerosis.